Navigation Links
Spherix Reports 3rd Quarter Earnings
Date:11/16/2007

BELTSVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has reported a loss from continuing operations of $3.1 million ($0.22 per share) and $7.1 million ($0.50 per share) for the three- and nine- months ended September 30, 2007, respectively. These losses exceeded the losses for the corresponding periods of 2006 due to increased expenditures related to the Company's Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes. The Company anticipates the trial to continue through mid-2009. Income from discontinued operations was $8.4 million ($0.59 per share) in the third quarter of 2007, and $8.3 million ($0.59 per share) for the nine months ended September 30, 2007, reflecting the sale of the InfoSpherix subsidiary (see Spherix press release dated August 16, 2007). The Company's total net income was $5.3 million (37 cents per share) and $1.3 million (9 cents per shared), respectively for the three- and nine-months ended September 30, 2007.

Claire L. Kruger, CEO, said, "The sale of InfoSpherix has provided the Company with significant funding that will help us to pursue the Company's strategic interests."

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue from continuing

operations $ 59,000 $ - $ 63,000 $ 3,000

Loss from continuing

operations $(3,122,000) $(981,000) $(7,063,000)$(2,350,000)

Income from discontinued

operations $ 8,416,000 $ 971,000 $ 8,321,000 $ 2,046,000

Net income
'/>"/>

SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Asthma treatment could   ...   treatments enter arena, says   GBI Research ... facing several of the leading asthma brands, such as ... (omalizumab), the global market for asthma treatment is set ... decade.   New analysis from business intelligence ...
(Date:5/29/2015)... , May 29, 2015 Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces that results of a ... uveal melanoma patients with hepatic metastases with the ... highlighted in an on-line abstract at the American ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences® today ... in which researchers utilized Caris Molecular Intelligence®, the ... potential therapeutic targets in patients with colorectal and ... programmed cell death protein 1 (PD-1) and its ... at the 2015 American Society of Clinical Oncology ...
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cytogenetics - Technologies, ... This report deals with cytogenetics in a ... to describe the chromosome structure and identify abnormalities ... biology, it is also referred to as molecular ...
Breaking Biology Technology:Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
... Therapeutics, Inc. (Nasdaq: HALO ) today announced ... patients who receive their insulin treatment with a ... Halozyme,s rHuPH20 (recombinant human hyaluronidase) with the active ingredient ... of action. These preliminary results represent the first reported ...
... Promising new devices for mechanical circulatory support of ... research, will be revealed this week at the International ... Meeting and Scientific Sessions. An update from the Pumps ... presented during the Meeting in San Diego.  PumpKIN is ...
Cached Biology Technology:Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 2Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 3Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... to tackle wheat,s worst enemy , Unlocking ancient rice ... in aphids, mouths, Reducing crop losses with cereals that ... better Indian varieties , Over 40 international research organisations ... will harness bioscience to improve food security in developing ...
... the physical process that creates that oh-so-alluring new car ... out, not particularly wholesome for sensitive satellite instruments, either. But ... to protect those instruments from its ill effects. ... car is its factory-fresh new car smell, a distinctive aroma ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... that its Board of Directors has declared a special cash ... total.  The special cash dividend will be paid on December ... 2012.  The Board of Directors has determined ...
Cached Biology News:Major international push to maximize bioscience research to help world's poorest farmers 2Major international push to maximize bioscience research to help world's poorest farmers 3Major international push to maximize bioscience research to help world's poorest farmers 4Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 2Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants 3Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total 2
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
... Nucleic acid hybridization Preparation Reconstitution: ... BSA, 50 mg ficoll and ... 5 ml of water yields ... molecular biology Density: 1.00 g/mL ...
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
... The ProteinChip Antibody ... assay development and optimization ... evaluate antibody-antigen interactions. This ... and differentiation of multiple ...
Biology Products: